{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007074","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.486174+00:00","generated_at":"2026-06-22T09:13:40.263097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corvus Q3 net loss $14.8M; cash $49.6M, CPI-818 data at ASH","bullets":["Net loss $14.8M for Q3 2022 vs $10.7M Q3 2021; R&D expense $10.4M (+$3.4M).","Cash, equivalents & securities $49.6M at Sep 30, 2022; projected year-end $40.5-42.5M.","CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR; new data at ASH Dec 2022.","Ciforadenant Phase 1b/2 in first-line RCC initiated with KCRC; up to 60 patients.","IND approved in China for mupadolimab Phase 1/1b combo with pembrolizumab in lung/head & neck cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007074","json":"https://secwatch.observer/filing/0001171843-22-007074.json","markdown":"https://secwatch.observer/filing/0001171843-22-007074.md","text":"https://secwatch.observer/filing/0001171843-22-007074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/0001171843-22-007074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/f8k_110322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:13:40.263097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64e98c0efdd1692548f5a28beb9b9ab8a60623bb","claim":"Corvus Pharmaceuticals, Inc. reported financial results for three and nine months ended September 30, 2022.","evidence_excerpt":"Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/0001171843-22-007074-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}